Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Proteomics analysis in post-transplant lymphoproliferative disorders.

Yazan Alsayed¹, Xavier Leleu, Alexey Leontovich

¹Hematology-Oncology, University of Pittsburgh, Pittsburgh, PA, USA.

European Journal of Haematology

|June 25, 2008

Summary

Post-transplant lymphoproliferative disorders (PTLDs) involve molecular changes in key cellular pathways. Targeting PI3K/mTOR, NFkB, and HSP90 proteins shows promise for PTLD treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026

Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026

Same author

New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.

Blood cancer discovery·2026

Same author

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026

Same author

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.

American journal of hematology·2026

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

Post-transplant lymphoproliferative disorders (PTLDs) are poorly understood lymphoid malignancies.
Identifying molecular drivers is crucial for developing targeted therapies.

Purpose of the Study:

To investigate protein-level molecular alterations in PTLD.
To identify dysregulated signaling pathways in PTLD.

Main Methods:

Protein microarray analysis was performed on six adult PTLD tumor samples and four benign lymph nodes.
Dysregulated proteins were identified using bioinformatics analysis.

Main Results:

Proteins within the PI3K/mTOR, NFkB, and HSP90 signaling pathways were found to be dysregulated in PTLD.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jul 4, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Inhibitors targeting these pathways induced significant cytotoxicity and apoptosis in both EBV-positive and EBV-negative cell lines.

Conclusions:

The PI3K/mTOR, NFkB, and HSP90 pathways are key molecular targets in PTLD.
These findings support the development of targeted therapeutic strategies for PTLD patients in future clinical trials.